PTPRC and neoplasm: We examined the expression of LILRB4 on tumor-infiltrating immune cells at different stages of tumor development and observed that LILRB4 expression increased on CD45+ cells as B16/F10 tumor progressed (day 14 tumor versus day 21 tumor; Fig. 1 C).